Playback speed
10 seconds
ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Ribociclib/Endocrine Therapy & Improved PFS with Capivasertib + Fulvestrant
By
ANCO’s ASCO Highlights 2019
FEATURING
Helen K. Chew
By
ANCO’s ASCO Highlights 2019
FEATURING
Helen K. Chew
461 views
September 12, 2019
Login to view comments.
Click here to Login